Ignite Creation Date:
2025-12-25 @ 2:49 AM
Ignite Modification Date:
2025-12-31 @ 2:20 PM
Study NCT ID:
NCT05074433
Status:
TERMINATED
Last Update Posted:
2025-10-17
First Post:
2021-10-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults
Sponsor:
Regeneron Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-10-25
Start Date Type:
ACTUAL
Primary Completion Date:
2022-05-18
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-05-18
Completion Date Type:
ACTUAL
First Submit Date:
2021-10-08
First Submit QC Date:
None
Study First Post Date:
2021-10-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-05-16
Results First Submit QC Date:
None
Results First Post Date:
2023-07-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-09
Last Update Post Date:
2025-10-17
Last Update Post Date Type:
ESTIMATED